RSV activity in Norway
Current respiratory syncytial virus (RSV) activity in Norway, based on ECDC ERVISS weekly data from the Norwegian Institute of Public Health (FHI).
Influenza: Low
Low
The source currently reports no meaningful activity (as of 16 Aug 2026).
Data window: Week 33 · Aug 10 – Aug 16 · Source: ECDC (weekly) · Source on seasonal break, next data from week 40
Get one free alert when the wave turns in Norway
We write exactly once: the moment the level goes up. No account, no newsletter. We store your address and the country, nothing else. Every mail has a one click unsubscribe. Privacy
View the last 8 weeks
In week 33 of 2026, Influenza activity in Norway is classified as low.
The source reports no meaningful activity across these weeks; a week-over-week percentage would be pure noise here.
The last 8 reported weeks
| Week | Relative | Level | vs prior week |
|---|---|---|---|
| Week 33 | – | Low | – |
| Week 32 | – | Low | – |
| Week 31 | – | Low | – |
| Week 30 | – | Low | – |
| Week 29 | – | Low | – |
| Week 28 | – | Low | – |
| Week 27 | – | Low | – |
| Week 26 | – | Low | – |
Across these weeks the source reports no meaningful activity, the values sit at the floor of its scale.
Current activity
- InfluenzaLowstableWeek 33Trend: stable · Week 33
- COVID-19LowrisingWeek 33Trend: rising · Week 33
- RSVLowstableWeek 33Trend: stable · Week 33
What this means
In week 33 of 2026, activity of respiratory syncytial virus (RSV) in Norway is low. The trend, derived from clinical surveillance, is stable. Over a four-week comparison, a clear decline is visible.
Data, context and methodology
The current picture for Norway is built on the European Respiratory Virus Surveillance Summary (ERVISS), published weekly by the European Centre for Disease Prevention and Control (ECDC). the Norwegian Institute of Public Health (FHI) via its sentinel GP network and wastewater surveillance is the national public-health authority that feeds ERVISS with sentinel primary care and virology data.
ECDC ERVISS
ERVISS is ECDC's weekly pan-European surveillance summary for influenza, SARS-CoV-2 and RSV. National authorities, in Norway's case the Norwegian Institute of Public Health (FHI) via its sentinel GP network and wastewater surveillance, submit harmonised indicators every week, which ECDC publishes in a standardised dataset on Thursdays. Using ERVISS rather than each country's native portal ensures cross-country comparability.
ILI / ARI consultation rates and positivity
the Norwegian Institute of Public Health (FHI) via its sentinel GP network and wastewater surveillance operates a sentinel network of general practices that report weekly rates of patients consulting for influenza-like illness (ILI) or acute respiratory infection (ARI). A subset of patients is swabbed and tested by reference laboratories, producing pathogen-specific positivity rates for flu, SARS-CoV-2 and RSV.
Why this source
Combining consultation incidence with virological positivity yields a pathogen-specific weekly incidence signal (ILI × positivity / 100). This is the standard European methodology and provides a more robust view than either indicator alone: consultation rates capture illness burden, positivity confirms which pathogen is driving it.
Qualitative classification
The “low”, “moderate” and “high” categories follow seasonal reference values and epidemiological thresholds calibrated to match our classifications for other countries. The ILI × positivity / 100 product is scaled to comparable thresholds using a divisor of 3, which aligns European sentinel peaks with the consultation-equivalent scale used elsewhere. Data refreshes weekly when ECDC publishes the latest ERVISS update, typically on Thursdays.
Source and seasonal pattern by pathogen
- Influenza
- The classification is based on the ECDC ERVISS weekly reports, drawing on data from the Norwegian Institute of Public Health (FHI) via its sentinel GP network and wastewater surveillance. Seasonally, infection waves in Norway typically peak between January and March; activity is usually markedly lower during the summer months.
- COVID-19
- The classification is based on the ECDC ERVISS weekly reports, drawing on COVID-19 surveillance data from the Norwegian Institute of Public Health (FHI) via its sentinel GP network and wastewater surveillance. Seasonally, infection waves in Norway typically peak during winter, with occasional summer waves driven by new variants; activity is usually markedly lower in late spring between waves.
- RSV
- The classification is based on the ECDC ERVISS weekly reports, drawing on RSV surveillance data from the Norwegian Institute of Public Health (FHI) via its sentinel GP network and wastewater surveillance. Seasonally, infection waves in Norway typically peak between December and February; activity is usually markedly lower in spring and summer.
Frequently asked questions
When is RSV season in Norway?
RSV activity in Norway typically begins rising in late autumn, peaks between December and February, and fades into spring. Post-pandemic seasons have been less predictable than pre-2020 patterns, with earlier or delayed peaks in some years. FHI publishes RSV indicators within its weekly respiratory-virus surveillance alongside flu and SARS-CoV-2, drawing on laboratory testing and hospital signals.
Who is most at risk from RSV in Norway?
The groups at highest risk of severe RSV are infants (particularly those under six months, preterm babies, and infants with underlying heart or lung disease) and older adults, especially those aged 75 and above or with chronic respiratory or cardiac conditions. In otherwise healthy children and adults, RSV usually resembles a common cold and resolves without complications.
Are RSV vaccines and nirsevimab available in Norway?
Since 2023, RSV vaccines have been authorised in the EU/EEA for older adults and for passive protection of infants. Norway has progressively adopted nirsevimab, the long-acting monoclonal antibody for infants entering their first RSV season, as part of the national childhood programme, and adult RSV vaccines are recommended by FHI for defined risk groups. Uptake and clinical impact are monitored through weekly surveillance.
How is RSV tracked in Norway?
RSV surveillance in Norway combines sentinel GP data, virological testing, and hospital-admission signals for severe paediatric and adult respiratory infection, with wastewater monitoring adding an early independent signal at selected sites. Weekly results are published by FHI and also reported to ECDC ERVISS, allowing direct comparison with Sweden, Finland, and other EU/EEA countries.
How does RSV differ from flu in Norwegian data?
In FHI surveillance, flu and RSV appear as separate positivity streams within the same respiratory panel. RSV disproportionately affects infants and the very elderly, while flu burden spreads across age bands and is especially severe in older adults. Symptom overlap between the two viruses is wide, so the distinction relies on laboratory testing rather than clinical impression.
More situation reports
Data last refreshed: Aug 31, 2026, 11:11. Update cadence: weekly.
This page is not medical advice and does not replace consultation with a healthcare professional. For specific symptoms, please contact a medical professional.
About this page
Published by Renderei Martin GmbH, Berlin. No commercial interest in individual health recommendations. The app is optionally monetised via a freemium subscription.
Content is based exclusively on the linked official surveillance publications. Medical statements are curated against the guidance of RKI, ECDC and WHO.
Methodology enquiries: press@infectrisk.com